Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment (HARMONY)
Vaihe 3, rinnakkaisryhmähoito, sokkoutettu, satunnaistettu, lumekontrolloitu tutkimus, jolla arvioidaan ihon alle annetun pegtibatinaasin tehoa ja turvallisuutta normaalin hoidon lisäksi osallistujille, joilla on kystationiinibeetasyntaasin puutteesta johtuva klassinen homokystinuria
Researchers are looking for a better way to treat people living with classical homocystinuria (HCU), a rare inherited condition. It is caused by changes in the cystathionine beta-synthase (or "CBS") gene and prevents an enzyme from working correctly in the body. This enzyme helps break down homocysteine, which is produced when the body processes methionine from protein-containing foods. This helps keep homocysteine and methionine at healthy levels. When this enzyme is not working, homocysteine and methionine build up in the blood and then spread into different tissues of the body and stop these body tissues from working normally.
People living with HCU can experience problems with their vision, bones, blood vessels, thinking, learning, and memory. Available treatments for HCU include a low-methionine diet (typically achieved by limiting protein-containing foods), a methionine-free protein supplement to help meet daily protein needs, and betaine (Cystadane®). These treatments are either not sufficient or are hard to take for many patients.
Pegtibatinase was designed by researchers to act like the CBS enzyme, which is missing or not working properly in people living with HCU. Researchers are studying whether adding pegtibatinase to standard treatment can lower homocysteine levels.
Researchers want to learn how safe and effective pegtibatinase is, how it moves through and affects the body, and how it may affect the daily lives of people with HCU.
The study plans to enroll participants from the US, Australia, Belgium, France, Germany, Ireland, Italy, Poland, Portugal, Qatar, Saudi Arabia, Spain, Turkey, and the United Kingdom. Many study visits may happen at home, depending on where you live and local regulations. Some visits may include a home nurse and telemedicine appointments with the study doctor.
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
Primary Objective:
Researchers want to learn more about how pegtibatinase will affect homocysteine and methionine levels when it is injected under the skin in participants already receiving standard treatment.
Blood tests will be used to measure changes in these levels during the study.
Secondary Objectives:
Researchers also want to learn:
- Is pegtibatinase safe and tolerable (how does it make participants feel)?
- How does pegtibatinase move throughout the body?
- Does pegtibatinase produce antibodies (proteins the body makes that may stop pegtibatinase from working or cause side effects)?
- How does pegtibatinase affect daily lives of participants with HCU? Researchers will use blood tests, urine tests, physical examinations, and questionnaires to answer these questions.
Study Population and Treatments:
This is a global study will include children and adults from 12 to 65 years old. Participants in the study will take their standard of care treatment. Participants will be put into 1 of 2 groups at random (like the flip of a coin) to take either:
- pegtibatinase, or
- an injection that does not have any medicine in it (or "placebo"). These are given as injections under the skin 2 times a week for up to 24 weeks. Neither the researchers nor the participant knows which treatment they are getting until the study is complete.
Study Duration and Visits:
Participants may be in the study for up to 38 weeks, including the screening period of up to 4 weeks, a pre-treatment period of up to 6 weeks where the participants will discuss their current diet with a dietitian (a health professional specialized in nutrition), a blinded treatment period of up to 24 weeks, and a safety follow-up visit completed 4 weeks after the last dose of study medication. Participants who complete the blinded treatment period may qualify to join the ENSEMBLE study before finishing the safety follow-up visit.
Participants who meet all study requirements may have up to 58 study visits. Visits may take place at a study center, at home, or by telemedicine.
These visits can include:
- Blood and urine tests
- Physical examinations
- Questionnaires
- Injections
- Questions about how they are feeling or any problems they are having
Safety / Adverse Events:
Researchers will monitor participants for any medical problems that occur during the study. Participants will have regular laboratory tests, health checkups, and study visits to monitor their health and safety.
Benefit-risk Conclusion:
Researchers have worked to reduce risks to participants in this study. They believe the risks of taking pegtibatinase in this study are justified by the potential benefits that they think pegtibatinase may have for people with HCU.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Travere Call Center
- Puhelinnumero: 1-877-659-5518
- Sähköposti: medinfo@travere.com
Opiskelupaikat
-
-
-
Adelaide, Australia
- Rekrytointi
- Royal Adelaide Hospital
-
Parkville, Australia
- Rekrytointi
- Royal Children's Hospital Melbourne
-
Westmead, Australia
- Rekrytointi
- Westmead Hospital
-
-
-
-
-
Brussels, Belgia
- Rekrytointi
- Cliniques Universitaires Saint-Luc
-
Edegem, Belgia
- Rekrytointi
- Universitair Ziekenhuis Antwerpen (UZA)
-
-
-
-
-
Barcelona, Espanja
- Rekrytointi
- Hospital Sant Joan de Déu
-
Madrid, Espanja
- Rekrytointi
- Hospital Universitario 12 de Octubre
-
Madrid, Espanja
- Rekrytointi
- Hospital Universitario Ramón y Cajal
-
Santiago de Compostela, Espanja
- Rekrytointi
- Complejo Hospitalario Universitario de Santiago (CHUS) - Hospital Clínico Universitario
-
Seville, Espanja
- Rekrytointi
- Hospital Universitario Virgen del Rocío
-
-
-
-
-
Dublin, Irlanti
- Rekrytointi
- Children's Health Ireland (CHI) at Temple Street
-
-
-
-
-
Bari, Italia
- Ei vielä rekrytointia
- Ospedale Pediatrico Giovanni XXIII
-
Genova, Italia
- Ei vielä rekrytointia
- IRCCS Istituto Giannina Gaslini
-
Milan, Italia
- Ei vielä rekrytointia
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Policlinico di Milano)
-
Monza, Italia
- Ei vielä rekrytointia
- Fondazione IRCCS San Gerardo Dei Tintori - Ospedale San Gerardo
-
Padova, Italia
- Ei vielä rekrytointia
- Azienda Ospedaliera di Padova
-
-
-
-
-
Coimbra, Portugali
- Rekrytointi
- Unidade Local de Saúde de Coimbra, EPE - Hospitais da Universidade de Coimbra
-
Lisbon, Portugali
- Rekrytointi
- Unidade Local de Saúde de Santa Maria, EPE - Hospital de Santa Maria
-
Porto, Portugali
- Ei vielä rekrytointia
- Unidade Local de Saúde de São João, EPE - Hospital São João
-
-
-
-
-
Krakow, Puola
- Ei vielä rekrytointia
- SP ZOZ Szpital Uniwersytecki w Krakowie
-
Warsaw, Puola
- Rekrytointi
- Instytut Pomnik-Centrum Zdrowia Dziecka
-
Warsaw, Puola
- Ei vielä rekrytointia
- Instytut Matki i Dziecka
-
-
-
-
-
Doha, Qatar
- Rekrytointi
- Hamad General Hospital
-
Doha, Qatar
- Rekrytointi
- Sidra Hospital
-
-
-
-
-
Paris, Ranska
- Rekrytointi
- Assistance Publique - Hôpitaux de Paris (AP-HP) - Hôpital Necker-Enfants Malades
-
Tours, Ranska
- Rekrytointi
- CHRU Hôpitaux de Tours - Hôpital Bretonneau
-
Vandœuvre-lès-Nancy, Ranska
- Rekrytointi
- Centre Hospitalier Régional Universitaire de Nancy (CHRU) - Hopitaux de Brabois - Hôpital d'enfants
-
-
-
-
-
Hamburg, Saksa
- Ei vielä rekrytointia
- Universitätsklinikum Hamburg-Eppendorf
-
Leipzig, Saksa
- Ei vielä rekrytointia
- Universitätsklinikum Leipzig
-
Münster, Saksa
- Ei vielä rekrytointia
- Universitätsklinikum Münster
-
-
-
-
-
Riyadh, Saudi-Arabia
- Rekrytointi
- King Abdullah International Medical Research Center
-
Riyadh, Saudi-Arabia
- Rekrytointi
- King Faisal Specialist Hospital and Research Centre (KFSHRC) - Riyadh
-
-
-
-
-
Ankara, Turkki (Türkiye)
- Rekrytointi
- Gazi University Hospital
-
Bornova, Turkki (Türkiye)
- Ei vielä rekrytointia
- Ege Üniversitesi Hastanesi Bornova
-
Istanbul, Turkki (Türkiye)
- Ei vielä rekrytointia
- Istanbul University Cerrahpasa Hospital
-
-
-
-
-
Birmingham, Yhdistynyt kuningaskunta
- Rekrytointi
- Birmingham Women's and Children's NHS Foundation Trust
-
Birmingham, Yhdistynyt kuningaskunta
- Rekrytointi
- University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital Birmingham
-
London, Yhdistynyt kuningaskunta
- Ei vielä rekrytointia
- University College London Hospitals NHS Foundation Trust - National Hospital for Neurology and Neurosurgery
-
Salford, Yhdistynyt kuningaskunta
- Rekrytointi
- Salford Royal NHS Foundation Trust - Salford Royal Hospital
-
-
-
-
Arizona
-
Phoenix, Arizona, Yhdysvallat, 85006
- Rekrytointi
- Phoenix Children's Hospital
-
-
Connecticut
-
New Haven, Connecticut, Yhdysvallat, 06519
- Rekrytointi
- Yale University School of Medicine
-
-
Georgia
-
Atlanta, Georgia, Yhdysvallat, 30322
- Rekrytointi
- Emory University
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60611
- Rekrytointi
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Maine
-
Portland, Maine, Yhdysvallat, 04102
- Rekrytointi
- Maine Health - Maine Medical Center
-
-
Maryland
-
Chevy Chase, Maryland, Yhdysvallat, 20815
- Rekrytointi
- Uncommon Cures
-
-
New York
-
New York, New York, Yhdysvallat, 10029
- Rekrytointi
- The Mount Sinai Hospital
-
-
North Carolina
-
Morrisville, North Carolina, Yhdysvallat, 27560
- Rekrytointi
- Science 37 - Virtual Site
-
-
Oregon
-
Portland, Oregon, Yhdysvallat, 97239
- Ei vielä rekrytointia
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Yhdysvallat, 19104
- Rekrytointi
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Yhdysvallat, 15224
- Rekrytointi
- University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh
-
-
Texas
-
Dallas, Texas, Yhdysvallat, 75390
- Rekrytointi
- University of Texas Southwestern Medical Center
-
-
Utah
-
Salt Lake City, Utah, Yhdysvallat, 84113
- Rekrytointi
- Utah Health - The University of Utah Primary Children's Hospital
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Must be ≥12 to ≤65 years of age, at the time of signing the informed consent
- Must have a diagnosis of classical HCU based on clinical, biochemical, and/or molecular genetic testing
- Plasma tHcy ≥80 µM at Screening visit, with allowance for up to 18 participants who may be enrolled with a Screening plasma tHcy ≥50 to <80 µM
- Participants who can become pregnant must have a negative pregnancy test before starting the study and must use a highly effective form of birth control (less than 1% risk of pregnancy per year) during the study and for at least 4 weeks after the last dose.
- Willing to maintain a generally stable diet for the duration of the study (unless changes are required based on medical/safety reasons)
- Willing to maintain generally stable intake and doses of betaine, pyridoxine, and medical food for the duration of the study (unless changes are required based on medical/safety reasons)
Exclusion Criteria:
- Diagnosis of Marfan syndrome, methylenetetrahydrofolate reductase (MTHFR) deficiency, or disorder of cobalamin metabolism
- Concurrent disease or condition (eg, history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, oncologic, or psychiatric disease) that would interfere with study participation or safety (excluding complications of HCU).
- History of major thrombotic event (eg, cerebrovascular accident, myocardial infarction, pulmonary embolism) in the previous 6 months.
- Body weight ≥160 kg.
- Use or planned use of any injectable drugs containing PEG (excluding PEG-containing vaccines)
- Any previous exposure to pegtibatinase and/or previous participation in a clinical study that included administration of pegtibatinase or pegtarviliase
- Prior severe immune reaction to a PEG-containing product
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Nelinkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Placebo Comparator: plasebo
|
volume-matched saline SC BIW |
|
Kokeellinen: pegtibatinaasi
|
Pegtibatinase BIW
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change from baseline in plasma tHcy levels - Weeks 6 to 12
Aikaikkuna: Weeks 6 - 12
|
Change between baseline and average of 6 to 12 week (6, 8, 10, and 12 week) plasma tHcy levels in participants receiving pegtibatinase vs. placebo. Baseline tHcy level defined as average of Week -3, Week -1, and Day 1 pre-dose plasma tHcy |
Weeks 6 - 12
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change from baseline in plasma tHcy levels - Weeks 16 to 24
Aikaikkuna: Weeks 16 - 24
|
Change between baseline and average of 16 to 24 week (16, 20, and 24 week) plasma tHcy levels in participants receiving pegtibatinase vs. placebo. Baseline tHcy level defined as average of Week -3, Week -1, and Day 1 pre-dose plasma tHcy |
Weeks 16 - 24
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Michael Imperiale, MD, Travere Therapeutics, Inc.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Aivojen sairaudet
- Keskushermoston sairaudet
- Hermoston sairaudet
- Aineenvaihdunta, synnynnäiset virheet
- Geneettiset sairaudet, synnynnäiset
- Metaboliset sairaudet
- Sidekudostaudit
- Aivosairaudet, Metaboliset, Synnynnäiset
- Aivosairaudet, aineenvaihdunta
- Aminohappoaineenvaihdunta, synnynnäiset virheet
- Hyperhomokysteinemia
- Synnynnäiset, perinnölliset ja vastasyntyneiden sairaudet ja poikkeavuudet
- Ravitsemukselliset ja aineenvaihduntataudit
- Iho- ja sidekudostaudit
- Homokystinuria
Muut tutkimustunnusnumerot
- TVTX-TVT058-301
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Requests for clinical trial data, including language stating its intended use, should be directed to datarequest@travere.com. If approved, the requested information will be provided to the requestor after signing a data access agreement. Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication. Travere reserves the right to decline or recommend modifications to a request if it does not comply with the data sharing policy or if it is determined that the request is made by a biased source.
IPD-jaon aikakehys
Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication.
IPD-jaon käyttöoikeuskriteerit
Requires submission and approval of intended use and a data sharing agreement.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .